Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs?
- 3 April 2007
- journal article
- editorial
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (6) , 316-317
- https://doi.org/10.1038/ncprheum0480
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonThe Lancet, 2007
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000